Neither Entyvio nor Stelara plus immunomodulators were as effective as other therapies for inflammatory bowel disease, according to research at Digestive Disease Week.

“When used with an immunomodulator (ie, azathioprine, methotrexate), anti-TNFs are associated with lower rates of anti-drug antibodies and increased rates of clinical remission but also with increased rates of infections,” Megan Lutz, MD, fellow at the University of Wisconsin School of Medicine and Public Health, told Healio Gastroenterology. “[Entyvio (vedolizumab, Takeda)] and [Stelara (ustekinumab, Janssen)]

Full Article: